Subscribe to RSS
Please copy the URL and add it into your RSS Feed Reader.
https://www.thieme-connect.de/rss/thieme/en/10.1055-s-00000069.xml
Semin Liver Dis 2007; 27(3): 295-311
DOI: 10.1055/s-2007-985074
DOI: 10.1055/s-2007-985074
The “C” of Viral Hepatitis in Children
Michael R. Narkewicz1 , Roniel Cabrera2 , Regino P. González-Peralta3- 1Pediatric Liver Center, Section of Pediatric Gastroenterology, Hepatology, and Nutrition, University of Colorado School of Medicine and The Children's Hospital, Denver, Colorado
- 2Section of Hepatobiliary Diseases, Division of Gastroenterology, Hepatology, and Nutrition, Department of Internal Medicine, University of Florida College of Medicine, Gainesville, Florida
- 3Pediatric Hepatology and Liver Transplantation, Division of Gastroenterology, Hepatology, and Nutrition, Department of Pediatrics, University of Florida College of Medicine, Gainesville, Florida
Further Information
Publication History
Publication Date:
08 August 2007 (online)
ABSTRACT
Chronic hepatitis C virus (HCV) infection is a major global health problem. The incidence of transfusion-related HCV infection has markedly decreased, and perinatal transmission has become the most important route of viral spread in children. Perinatally acquired HCV infection is generally a benign condition, but severe liver disease can occur. Little is known about the risk factors for the progression of liver disease in children, and few well-designed pediatric clinical trials have been conducted. Therefore, the decision to treat (or not) children with this viral pathogen is currently a contentious endeavor. Herein, we describe the virus and its life cycle and summarize our current understanding of the epidemiology and natural history of perinatally acquired infection and review current and future therapy of HCV infection in children.
KEYWORDS
Hepatitis C virus - children - transmission - treatment
REFERENCES
- 1 Shepard C W, Finelli L, Alter M J. Global epidemiology of hepatitis C virus infection. Lancet Infect Dis. 2005; 5 558-567
- 2 World Health Organization . Hepatitis C. Wkly Epidemiol Rec. 1997; 72 65-72
- 3 Wong J B, McQuillan G M, McHutchison J G, Poynard T. Estimating future hepatitis C morbidity, mortality, and costs in the United States. Am J Public Health. 2000; 90 1562-1569
- 4 Jhaveri R, Grant W, Kauf T L, McHutchison J. The burden of hepatitis C virus infection in children: estimated direct medical costs over a 10-year period. J Pediatr. 2006; 148 353-358
- 5 Donahue J G, Munoz A, Ness P M et al.. The declining risk of post-transfusion hepatitis C virus infection. N Engl J Med. 1992; 327 369-373
- 6 Robertson B, Myers G, Howard C et al.. Classification, nomenclature, and database development for hepatitis C virus (HCV) and related viruses: proposals for standardization. Arch Virol. 1998; 143 2493-2503
- 7 Branch A D, Stump D D, Gutierrez J A, Eng F, Walewski J L. The hepatitis C virus alternate reading frame (ARF) and its family of novel products: the alternate reading frame protein/F-protein, the double-frameshift protein, and others. Semin Liver Dis. 2005; 25 105-117
-
8 Thomson M, Liang T J.
Molecular biology of hepatitis C virus . In: Liang TJ, Hoofnagle JH Hepatitis C. San Diego, CA; Academic Press 2000: 1-23 -
9 Smith R M, Wu G Y.
Molecular virology of hepatitis B and C . In: Koff RS, Wu GY Chronic Viral Hepatitis: Diagnosis and Therapeutics. Totowa, NJ; Humana Press 2002: 1-24 - 10 Tellinghuisen T L, Rice C M. Interaction between hepatitis C virus proteins and host cell factors. Curr Opin Microbiol. 2002; 5 419-427
- 11 Martell M, Esteban J I, Quer J et al.. Hepatitis C virus circulates as a population of different but closely related genomes: quasispecies nature of HCV genome distribution. J Virol. 1992; 66 3225-3229
- 12 Moribe T, Hayashi N, Kanasawa Y et al.. Hepatitis C viral complexity detected by single strand conformational polymorphism and response to interferon therapy. Gastroenterology. 1995; 108 789-795
- 13 González-Peralta R P, Qian K, She J Y et al.. Clinical implications of viral quasispecies in chronic hepatitis C. J Med Virol. 1996; 49 242-247
- 14 González-Peralta R P, Liu W, Davis G L et al.. Modulation of hepatitis C virus quasispecies heterogeneity by interferon-alpha and ribavirin. J Viral Hepat. 1997; 4 99-106
- 15 Canobio S, Guilbert C M, Troesch M et al.. Differing patterns of liver disease progression and hepatitis C virus (HCV) quasispecies evolution in children vertically coinfected with HCV and human immunodeficiency virus type 1. J Clin Microbiol. 2004; 42 4365-4369
- 16 Ishii T, Ohto H, Takeuchi C et al.. Evolution in the hypervariable region of the hepatitis C virus in two infants infected by mother-to-infant transmission. Pediatr Int. 2005; 47 278-285
- 17 Farci P, Quinti I, Farci S et al.. Evolution of hepatitis C viral quasispecies and hepatic injury in perinatally infected children followed prospectively. Proc Natl Acad Sci USA. 2006; 103 8475-8480
- 18 Caudai C, Battiata M, Riccardi M P et al.. Vertical transmission of the hepatitis C virus to infants of anti-human immunodeficiency virus-negative mothers: molecular evolution of hypervariable region 1 in prenatal and perinatal or postnatal infections. J Clin Microbiol. 2003; 41 3955-3959
- 19 Lau J YN, Davis G L, Prescott L E et al.. Distribution of hepatitis C virus genotypes determined by line probe assay in patients with chronic hepatitis C seen at tertiary referral centers in the United States. Ann Intern Med. 1996; 124 868-876
- 20 Jara P, Resti M, Hierro L et al.. Chronic hepatitis C virus infection in childhood: clinical patterns and evolution in 224 white children. Clin Infect Dis. 2003; 36 275-280
- 21 Wirth S, Lang T, Gehring S, Gerner P. Recombinant alfa-interferon plus ribavirin therapy in children and adolescents with chronic hepatitis C. Hepatology. 2002; 36 1280-1284
- 22 González-Peralta R P, Kelly D A, Haber B for the International Pediatric Hepatitis C Therapy Group et al. Interferon alfa-2b in combination with ribavirin for the treatment of chronic hepatitis C in children: efficacy, safety, and pharmacokinetics. Hepatology. 2005; 42 1010-1018
- 23 Jacobson K R, Murray K, Zellos A, Schwarz K B. An analysis of published trials of interferon monotherapy in children with chronic hepatitis C. J Pediatr Gastroenterol Nutr. 2002; 34 52-58
- 24 Jonas M M, Ott M J, Nelson S P et al.. Interferon-alpha treatment of chronic hepatitis C virus infection in children. Pediatr Infect Dis J. 1998; 17 241-246
- 25 Matsuoka S, Tatara K, Hayabuchi Y et al.. Serologic, virologic, and histologic characteristics of chronic phase hepatitis C virus disease in children infected by transfusion. Pediatrics. 1994; 94 919-922
- 26 Garcia-Monzon C, Jara P, Fernandez-Bermejo M et al.. Chronic hepatitis C in children: a clinical and immunohistochemical comparative study with adult patients. Hepatology. 1998; 28 1696-1701
- 27 Brass V, Moradpour D, Blum H E. Molecular virology of hepatitis C virus: 2006 update. Int J Med Sci. 2006; 3 29-34
- 28 Lindenbach B D, Rice C M. Unraveling hepatitis C virus replication from genome to function. Nature. 2005; 436 933-938
- 29 Evans M J, von Hahn T, Tscherne D M et al.. Claudin-1 is a hepatitis C virus co-receptor required for a late step in entry. Nature. 2007; 446 801-805
- 30 Cocquerel L, Voisset C, Dubuisson J. Hepatitis C virus entry: potential receptors and their biological functions. J Gen Virol. 2006; 87 1075-1084
- 31 Spahn C M, Kieft J S, Grassucci R A et al.. Hepatitis C virus IRES RNA-induced changes in the conformation of the 40S ribosomal subunit. Science. 2001; 291 1959-1962
- 32 Gosert R, Egger D, Lohmann V et al.. Identification of the hepatitis C virus RNA replication complex in Huh-7 cells harboring subgenomic replicons. J Virol. 2003; 77 5487-5492
- 33 Quinkert D, Bartenschlager R, Lohmann V. Quantitative analysis of the hepatitis C virus replication complex. J Virol. 2005; 79 13594-13605
- 34 Sakai A, Claire M S, Faulk K et al.. The p7 polypeptide of hepatitis C virus is critical for infectivity and contains functionally important genotype-specific sequences. Proc Natl Acad Sci USA. 2003; 100 11646-11651
- 35 Yi M, Ma Y, Yates J, Lemon S M. Compensatory mutations in E1, p7, NS2, and NS3 enhance yields of cell culture-infectious intergenotypic chimeric hepatitis C virus. J Virol. 2007; 81 629-638
- 36 Haqshenas G, Mackenzie J M, Dong X, Gowans E J. Hepatitis C virus p7 protein is localized in the endoplasmic reticulum when it is encoded by a replication-competent genome. J Gen Virol. 2007; 88 134-142
- 37 Neumann A U, Lam N P, Dahari H et al.. Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-α therapy. Science. 1998; 282 103-107
- 38 Alter M J, Kruszon-Moran D, Nainan O V et al.. The prevalence of hepatitis C virus infection in the United States, 1988 through 1994. N Engl J Med. 1999; 341 556-562
- 39 Bortolotti F, Jorio R, Resti M et al.. Epidemiological profile of 806 Italian children with hepatitis C virus infection over a 15-year period. J Hepatol. 2007; 46 783-790
- 40 Roberts E A, Yeung L. Maternal-infant transmission of hepatitis C virus infection. Hepatology. 2002; 36(suppl 1) S106-S113
- 41 European Paediatric Hepatitis C Virus Network . A significant sex-but not elective cesarean section-effect on mother-to-child transmission of hepatitis C virus infection. J Infect Dis. 2005; 192 1872-1879
- 42 Dore G J, Kaldor J M, McCaughan G W. Systematic review of role of polymerase chain reaction in defining infectiousness among people infected with hepatitis C virus. BMJ. 1997; 315 333-337
- 43 Pappalardo B L. Influence of maternal human immunodeficiency virus (HIV) co-infection on vertical transmission of hepatitis C virus (HCV): a meta-analysis. Int J Epidemiol. 2003; 32 727-734
- 44 Gibb D M, Goodall R L, Dunn D T et al.. Mother-to-child transmission of hepatitis C virus: evidence for preventable peripartum transmission. Lancet. 2000; 356 904-907
- 45 Ferrero S, Lungaro P, Bruzzone B M, Gotta C, Bentivoglio G, Ragni N. Prospective study of mother-to-infant transmission of hepatitis C virus: a 10-year survey (1990-2000). Acta Obstet Gynecol Scand. 2003; 82 229-234
- 46 Giacchino R, Tasso L, Timitilli A et al.. Vertical transmission of hepatitis C virus infection: usefulness of viremia detection in HIV-seronegative hepatitis C virus-seropositive mothers. J Pediatr. 1998; 132 167-169
- 47 Okamoto M, Nagata I, Murakami J et al.. Prospective reevaluation of risk factors in mother-to-child transmission of hepatitis C virus: high virus load, vaginal delivery, and negative anti-NS4 antibody. J Infect Dis. 2000; 182 1511-1514
- 48 Resti M, Azzari C, Mannelli F et al.. Mother to child transmission of hepatitis C virus: prospective study of risk factors and timing of infection in children born to women seronegative for HIV-1. Tuscany Study Group on Hepatitis C Virus Infection. BMJ. 1998; 317 437-441
- 49 Steininger C, Kundi M, Jatzko G, Kiss H, Lischka A, Holzmann H. Increased risk of mother-to-infant transmission of hepatitis C virus by intrapartum infantile exposure to maternal blood. J Infect Dis. 2003; 187 345-351
- 50 Tajiri H, Miyoshi Y, Funada S et al.. Prospective study of mother-to-infant transmission of hepatitis C virus. Pediatr Infect Dis J. 2001; 20 10-14
- 51 Zanetti A R, Tanzi E, Romano L et al.. A prospective study on mother-to-infant transmission of hepatitis C virus. Intervirology. 1998; 41 208-212
- 52 Azzari C, Resti M, Moriondo M, Ferrari R, Lionetti P, Vierucci A. Vertical transmission of HCV is related to maternal peripheral blood mononuclear cell infection. Blood. 2000; 96 2045-2048
- 53 Conte D, Fraquelli M, Prati D, Colucci A, Minola E. Prevalence and clinical course of chronic hepatitis C virus (HCV) infection and rate of HCV vertical transmission in a cohort of 15,250 pregnant women. Hepatology. 2000; 31 751-755
- 54 Paccagnini S, Principi N, Massironi E et al.. Perinatal transmission and manifestation of hepatitis C virus infection in a high risk population. Pediatr Infect Dis J. 1995; 14 195-199
- 55 Resti M, Azzari C, Galli L et al.. Maternal drug use is a preeminent risk factor for mother-to-child hepatitis C virus transmission: results from a multicenter study of 1372 mother-infant pairs. J Infect Dis. 2002; 185 567-572
- 56 European Paediatric Hepatitis C Virus Network . Effects of mode of delivery and infant feeding on the risk of mother-to-child transmission of hepatitis C virus. BJOG. 2001; 108 371-377
- 57 McIntyre P G, Tosh K, McGuire W. Caesarean section versus vaginal delivery for preventing mother to infant hepatitis C virus transmission. Cochrane Database Syst Rev. 2006; (4) CD005546
- 58 Pembrey L, Newell M L, Tovo P A. The management of HCV infected pregnant women and their children. European Paediatric HCV Network. J Hepatol. 2005; 43 515-525
- 59 Davies G, Wilson R D, Desilets V et al.. Amniocentesis and women with hepatitis B, hepatitis C, or human immunodeficiency virus. J Obstet Gynaecol Can. 2003; 25 145-152
- 60 Mok J, Pembrey L, Tovo P A, Newell M L. When does mother to child transmission of hepatitis C virus occur?. Arch Dis Child Fetal Neonatal Ed. 2005; 90 F156-F160
- 61 Kumar R M, Shahul S. Role of breast-feeding in transmission of hepatitis C virus to infants of HCV-infected mothers. J Hepatol. 1998; 29 191-197
- 62 Lin H H, Kao J H, Hsu H Y et al.. Absence of infection in breast-fed infants born to hepatitis C virus-infected mothers. J Pediatr. 1995; 126 589-591
- 63 Della Bella S, Riva A, Tanzi E et al.. Hepatitis C virus-specific reactivity of CD4 + -lymphocytes in children born from HCV-infected women. J Hepatol. 2005; 43 394-402
- 64 Martinetti M, Pacati I, Daielli C, Salvaneschi L, Maccabruni A. Critical role of Val/Gly86 HLA-DRB dimorphism in the neonatal resistance or susceptibility to maternal hepatitis C virus infection. Pediatr Infect Dis J. 1997; 16 1001-1002
- 65 Mast E E, Hwang L Y, Seto D S et al.. Risk factors for perinatal transmission of hepatitis C virus (HCV) and the natural history of HCV infection acquired in infancy. J Infect Dis. 2005; 192 1880-1889
- 66 Polywka S, Pembrey L, Tovo P A, Newell M L. Accuracy of HCV-RNA PCR tests for diagnosis or exclusion of vertically acquired HCV infection. J Med Virol. 2006; 78 305-310
- 67 Resti M, Jara P, Hierro L et al.. Clinical features and progression of perinatally acquired hepatitis C virus infection. J Med Virol. 2003; 70 373-377
- 68 Jara P, Resti M, Hierro L et al.. Chronic hepatitis C virus infection in childhood: clinical patterns and evolution in 224 white children. Clin Infect Dis. 2003; 36 275-280
- 69 European Paediatric Hepatitis C Virus Network . Three broad modalities in the natural history of vertically acquired hepatitis C virus infection. Clin Infect Dis. 2005; 41 45-51
- 70 Casiraghi M A, De Paschale M, Romano L et al.. Long-term outcome (35 years) of hepatitis C after acquisition of infection through mini transfusions of blood given at birth. Hepatology. 2004; 39 90-96
- 71 McDiarmid S V, Anand R. SPLIT Research Group . Studies of pediatric liver transplantation (SPLIT): a summary of the 2003 annual report. Clin Transpl. 2003; 119-130
- 72 Rumbo C, Fawaz R L, Emre S H et al.. Hepatitis C in children: a quaternary referral center perspective. J Pediatr Gastroenterol Nutr. 2006; 43 209-216
- 73 González-Peralta R P, Langham M R, Mohan P, Colombani P M, Alford M K, Schwarz K B. Hepatocellular carcinoma in two adolescents with chronic hepatitis C virus infection. J Pediatr Gastroenterol Nutr. 2003; 37 380 (Abstract)
- 74 Iorio R, Giannattasio A, Sepe A, Terracciano L M, Vecchione R, Vegnente A. Chronic hepatitis C in childhood: an 18-year experience. Clin Infect Dis. 2005; 41 1431-1437
- 75 Shneider B L, González-Peralta R P, Roberts E A. Controversies in the management of pediatric liver diseases: hepatitis B, C and NAFLD. Hepatology. 2006; 44 1344-1354
- 76 Feld J J, Hoofnagle J H. Mechanism of action of interferon and ribavirin in treatment of hepatitis C. Nature. 2005; 436 967-972
- 77 de Veer M J, Holko M, Frevel M et al.. Functional classification of interferon-stimulated genes identified using microarrays. J Leukoc Biol. 2001; 69 912-920
- 78 Sen G C. Viruses and interferons. Annu Rev Microbiol. 2001; 55 255-281
- 79 Shindo M, Di Bisceglie A M, Cheung L et al.. Decrease in serum hepatitis C viral RNA during alpha-interferon therapy for chronic hepatitis C. Ann Intern Med. 1991; 115 700-704
- 80 Davis G L. Treatment of acute and chronic hepatitis C. Clin Liver Dis. 1997; 1 615-630
- 81 Jacobson K R, Murray K, Zellos A, Schwarz K B. An analysis of published trials of interferon monotherapy in children with chronic hepatitis C. J Pediatr Gastroenterol Nutr. 2002; 34 52-58
- 82 Davis G L, Esteban-Mur R, Rustgi V et al.. Interferon alfa-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C. International Hepatitis Interventional Therapy Group. N Engl J Med. 1998; 339 1493-1499
- 83 McHutchison J G, Gordon S C, Schiff E R et al.. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group. N Engl J Med. 1998; 339 1485-1492
- 84 Christensson B, Wiebe T, Akesson A, Widell A. Interferon-alpha and ribavirin treatment of hepatitis C in children with malignancy in remission. Clin Infect Dis. 2000; 30 585-586
- 85 Lackner H, Moser A, Deutsch J et al.. Interferon-alpha and ribavirin in treating children and young adults with chronic hepatitis C after malignancy. Pediatrics. 2000; 106 E53-E56
- 86 Wirth S, Lang T, Gehring S, Gerner P. Recombinant alfa-interferon plus ribavirin therapy in children and adolescents with chronic hepatitis C. Hepatology. 2002; 36 1280-1284
- 87 González-Peralta R P, Glue P, Hodik M, Davis G L, Lau J YN. Single-dose pharmacokinetics of interferon alfa2b in children with chronic hepatitis C. Hepatology. 1999; 30 264A
- 88 Manns M P, McHutchison J G, Gordon S C et al.. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet. 2001; 358 958-965
- 89 Fried M W, Shiffman M L, Reddy K R et al.. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med. 2002; 347 975-982
- 90 Schwarz K B, Mohan P, Narkewicz M R et al.. The safety, efficacy, and pharmacokinetics of peginterferon alfa-2b (40kD) in children with chronic hepatitis C. J Pediatr Gastroenterol Nutr. 2006; 43 499-505
- 91 Wirth S, Pieper-Boustani H, Lang T et al.. Peginterferon alfa-2b plus ribavirin treatment in children and adolescents with chronic hepatitis C. Hepatology. 2005; 41 1013-1018
- 92 Davis G L, Wong J B, McHutchison J G, Manns M P, Harvey J, Albrecht J. Early virologic response to treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C. Hepatology. 2003; 38 645-652
- 93 Polifka J E, Friedman J M. Developmental toxicity of ribavirin/IFalpha combination therapy: is the label more dangerous than the drugs?. Birth Defects Res A Clin Mol Teratol. 2003; 67 8-12
- 94 Barlow C F, Priebe C J, Mulliken J B et al.. Spastic diplegia as a complication of interferon alfa-2a treatment of hemangiomas of infancy. J Pediatr. 1998; 132 527-530
- 95 Murray K F, Barton B, González-Peralta R P for the PEDS-C Clinical Research Network et al. Development of a multi-center, randomized controlled trial for children with chronic hepatitis C (PEDS-C). J Pediatr Gastroenterol Nutr. 2005; 41 524 (Abstract)
-
96 U.S. Code of Federal Regulations .Title 21, Food and Drugs: 314.55 and 601.27.
- 97 Balan V, Nelson D R, Sulkowski M S et al.. Phase I/II study evaluating escalating subcutaneous doses of recombinant human albumin-interferon-alpha fusion protein in chronic hepatitis C patients who have failed previous interferon-alpha-based therapy. Antivir Ther. 2006; 11 35-45
- 98 Bain V G, Kaita K D, Yoshida E M et al.. A phase 2 study to evaluate the antiviral activity, safety, and pharmacokinetics of recombinant human albumin-interferon alfa fusion protein in genotype 1 chronic hepatitis C patients. J Hepatol. 2006; 44 671-678
- 99 Gish R G. Treating HCV with ribavirin analogues and ribavirin-like molecules. J Antimicrob Chemother. 2006; 57 8-13
- 100 Gish R G, Arora S, Reddy K R et al.. Virological response and safety outcomes in therapy-naïve patients treated for chronic hepatitis C with taribavirin or ribavirin in combination with pegylated interferon alfa-2a: a randomized, phase 2 study. J Hepatol. 2007; 47 51-59
- 101 Benhamou Y, Pockros P, Rodriquez-Torres M et al.. The safety and efficacy of viramidine plus pegylated interferon alfa-2b versus ribavirin plus pegylated interferon alfa-2b in therapy-naïve patients infected with HCV: phase 3 results. J Hepatol. 2006; 44(suppl 2) S273
- 102 McHutchison J G, Shiffman M L, Cheung R C et al.. A randomized, double-blind, placebo-controlled dose-escalation trial of merimepodib (VX-497) and interferon-alpha in previously untreated patients with chronic hepatitis C. Antivir Ther. 2005; 10 635-643
- 103 Pockros P J, Pessoa M G, Diago M et al.. Combination of levovirin and peginterferon alfa-2a fails to generate virological response comparable to ribavirin and peginterferon alfa-2a in patients with chronic hepatitis C. Hepatology. 2004; 40(suppl) 391A
- 104 Welbourn S, Green R, Gamache I et al.. Hepatitis C virus NS2/3 processing is required for NS3 stability and viral RNA replication. J Biol Chem. 2005; 280 29604-29611
- 105 Grakoui A, McCourt D W, Wychowski C, Feinstone S M, Rice C M. Characterization of the hepatitis C virus-encoded serine proteinase: determination of proteinase-dependent polyprotein cleavage sites. J Virol. 1993; 67 2832-2843
- 106 Foy E, Li K, Wang C et al.. Regulation of interferon regulatory factor-3 by the hepatitis C virus serine protease. Science. 2003; 300 1145-1148
- 107 Lemon S M, Yi M, Li K. “Strong reasons make strong actions”-the antiviral efficacy of NS3/4A protease inhibitors. Hepatology. 2005; 41 671-674
- 108 Hinrichsen H, Benhamou Y, Wedemeyer H et al.. Short-term antiviral efficacy of BILN 2061, a hepatitis C virus serine protease inhibitor, in hepatitis C genotype 1 patients. Gastroenterology. 2004; 127 1347-1355
- 109 Reesink H W, Zeuzem S, Weegink C J et al.. Final results of a phase 1b, multiple-dose study of VX-950, a hepatitis C virus protease inhibitor. Hepatology. 2005; 42 234A
- 110 Reesink H W, Zeuzem S, Weegink C J et al.. Initial results of a 14-day study of the hepatitis C virus inhibitor VX-950, in combination with peginterferon-alfa 2a. J Hepatol. 2006; 44(suppl 2) S272
- 111 Lawitz E, Rodriguez-Torres M, Muir A et al.. 28 days of the hepatitis C protease inhibitor VX-950, in combination with peg-interferon-alfa-2a and ribavirin, is well-tolerated and demonstrates robust antiviral effects. Gastroenterology. 2006; 130(suppl 2) A686
- 112 Zeuzem S, Sarrazin C, Rouzier R et al.. Anti-viral activity of SCH 503034, a HCV protease inhibitor, administered as monotherapy in hepatitis C genotype-1 (HCV-1) patients refractory to pegylated interferon (peg-IFN-α). Hepatology. 2005; 42 233A
- 113 Zeuzem S, Sarrazin C, Wagner F et al.. Combination therapy with the HCV protease inhibitor, SCH 503034, plus PEG-Intron in hepatitis C genotype-1 PEG-Intron non-responders: phase Ib results. Hepatology. 2005; 42 276A
- 114 Gale M, Foy E. Evasion of intracellular host defense by hepatitis C virus. Nat Med. 2005; 436 939-945
- 115 Zeuzem S, Sarrazin C, Rouzier R et al.. Anti-viral activity of SCH 503034, a HCV protease inhibitor, administered as monotherapy in hepatitis C genotype-1 (HCV-1) patients refractory to pegylated interferon (peg-IFN-α). Hepatology. 2005; 42 233A
- 116 Kieffer T, Sarrazin C, Miller J et al.. Combination of telaprevir (VX-950) and PEG-IFN-alfa suppressed both wild-type virus and resistance variants in HCV genotype 1-infected patients in a 14-day phase 1B study. Hepatology. 2006; 44 222A
- 117 Kieffer T, Sarrazin C, Bartels D et al.. Wild-type HCV NS3 protease re-emerges during follow-up after 14 days of dosing with VX-950 in patients with genotype 1 HCV. J Hepatol. 2006; 44(suppl 2) S7
- 118 O'Brien C, Godofsky E, Roriguez-Torres M et al.. Randomized trial of valopicitabine (NM283) alone or with PEG-interferon vs. retreatment with PEG-interferon plus ribavirin (PEGIFN/RBV) in hepatitis C patients with previous non-response to PEGIFN.RBV: first interim results. Hepatology. 2005; 42 232A
- 119 Dieterich D, Lawitz E, Nguyen T et al.. Early clearance of HCV RNA with valopicitabine (NM283) plus peg-interferon in treatment-naïve patients with HCV-1 infection: first results from a phase IIb trial. J Hepatol. 2006; 44(suppl 2) S271-S272
- 120 Roberts S, Cooksley G, Dore G et al.. Results of a phase 1B multiple dose study of R1626 a novel nucleoside analog targeting HCV polymerase in chronic HCV genotype 1 patients. Hepatology. 2006; 44 692A
- 121 Chandra P, Raible D, Harper D, Speth J, Villano S, Bichier G. Antiviral activity of the non-nucleoside polymerase inhibitor HCV-796 in patients with chronic hepatitis C virus: preliminary results from a randomized, double-blind, placebo-controlled, ascending multiple dose study. Gastroenterology. 2006; 130(suppl 2) A748
Regino P González-PeraltaM.D.
Pediatric Gastroenterology, Hepatology, and Nutrition
P.O. Box 100296, University of Florida College of Medicine, Gainesville, FL 32610